ACC 2021 This subanalysis of GALACTIC-HF showed that the treatment benefits of omecamtiv mecarbil on the primary outcome of first HF event or CV death improve with decreasing EF.
ACC 2021 In patients undergoing coronary angiography in the INSPIRE registry, higher levels of EPA unadjusted and adjusted for DHA were associated with lower MACE and in contrast, higher DHA levels adjusted for EPA were associated with higher MACE.
ACC 2021 Ablation-based rhythm control and rate control showed no statistically significant differences in the RAFT-AF trial for the primary outcome of all-cause mortality and HF events in patients with HF and high burden AF.
ACC 2021 Myocardial extracellular volume was reduced by treatment with pirfenidone, an anti-fibrotic medication, after 52 weeks compared to placebo in patients with HFpEF and evidence of myocardial fibrosis.
ACC 2021 De-escalation DAPT with clopidogrel 1 month after PCI reduced the composite outcome of ischemic and bleeding events in acute MI patients compared to the active control group.
ACC 2021 REHAB-HF showed that individualized physical rehabilitation intervention, compared to usual care, resulted in significant improvements in physical function, frailty status, quality of life, and depression in older patients with ADHF.
ACC 2021 A phase 2 study showed that evinacumab resulted in reduction of TGs in patients with severe hypertriglyceridemia, but lowering was variable and dependent on genotype.
ACC 2021 Results from the HOLIDAY study suggest that just one alcoholic drink was associated with a 2-fold greater odds and two or more alcoholic drinks were associated with a 3.5-fold greater odds of a discrete AF episode occurring in the next four hours.
ACC 2021 Prof. Ridker talks about anti-inflammatory therapies to prevent CVD: What is the right drug and what is the right target population?
ACC 2021 The phase 2 RESCUE trial showed that the IL-6 inhibitor ziltivekimab largely reduced hsCRP and other biomarkers of inflammation and thrombosis in patients with CKD and ≥2 mg/L hsCRP.
ACC 2021 Risk of new-onset AF was reduced by 29% in patients randomized to finerenone compared to placebo in a population of patients with T2DM and CKD.
ACC 2021 The LIFE trial showed that sacubitril/valsartan was not superior to valsartan with respect to changing NT-proBNP levels in patients with advanced HF.